Shares of 10x Genomics, Inc. (TXG) surged 13.38% in pre-market trading on Friday, following the release of the company's impressive third-quarter 2025 financial results and a wave of positive analyst reactions. The biotech firm, known for its innovative genomics and single-cell analysis technologies, reported better-than-anticipated earnings and revenue figures, sparking investor enthusiasm.
For the third quarter, 10x Genomics posted earnings per share (EPS) of $(0.22), beating the estimated $(0.29). Revenue came in at $149.002 million, surpassing the forecast of $142.490 million. The company's gross margin stood at a healthy 67%, indicating strong profitability in its core operations. Despite reporting a net loss of $27.5 million for the quarter, the narrower-than-expected loss bolstered investor confidence.
Adding to the positive sentiment, 10x Genomics provided an optimistic outlook for the fourth quarter, projecting revenue between $154 million and $158 million, which exceeded analysts' expectations of $154.1 million. This forward-looking guidance suggests continued growth and appears to have contributed significantly to the stock's pre-market rally. In response to the strong results and outlook, several analysts have raised their price targets for 10x Genomics. JP Morgan increased its target price to $15 from $13, while Barclays raised its target to $17 from $15, further fueling investor optimism. The combination of better-than-expected financial performance, upbeat guidance, and positive analyst revisions has created a perfect storm for 10x Genomics' stock, driving the substantial pre-market gain.
Comments